Literature DB >> 3161116

Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule.

L S Seiden, J L Dahms, R A Shaughnessy.   

Abstract

Those antidepressant drugs that are in wide clinical use decrease response rate and increase reinforcement rate when administered to rats performing on a differential-reinforcement-of-low-rate 72-s (DRL 72-s) schedule. Drugs that are not antidepressants do not have this effect. In this experiment, the following were examined for their effects on a DRL 72-s schedule: trazodone, zimelidine, fluoxetine, and bupropion (atypical antidepressants); electroconvulsive shock (ECS, which is an effective treatment for depression); and haloperidol and clozapine (antipsychotic drugs). Trazodone (3.12-25.00 mg/kg), fluoxetine (10-20 mg/kg), and ECS decreased response rate and increased reinforcement rate. Zimelidine (20 mg/kg) increased reinforcement rate and nonsignificantly decreased response rate. At doses between 2.5 and 40 mg/kg, bupropion had no effect on reinforcement rate or response rate, but at 60 mg/kg response rate was increased and reinforcement rate was nonsignificantly decreased. At the higher dose, the effects of bupropion resemble those of a psychomotor stimulant. Haloperidol (0.04 mg/kg) and clozapine (2.5-10.0 mg/kg) decreased response rate and reinforcement rate. These results suggest that the DRL 72-s schedule may be useful for testing the antidepressant potential of new drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161116     DOI: 10.1007/bf00431684

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Effects of alcohol on timing behavior.

Authors:  V G LATIES; B WEISS
Journal:  J Comp Physiol Psychol       Date:  1962-02

2.  Effect of trazodone, mianserin, iprindole and zimelidine on wet dog shakes produced by carbachol in rats.

Authors:  L Turski; S J Czuczwar; W Turski; Z Kleinrok
Journal:  J Pharm Pharmacol       Date:  1981-10       Impact factor: 3.765

3.  Profile of antidepressant action of zimelidine and norzimelidine compared with amitriptyline.

Authors:  S A Montgomery; D B Montgomery; R McAuley; S J Rani; D Roy
Journal:  Adv Biochem Psychopharmacol       Date:  1982

4.  A comparative study of bupropion and amitriptyline in depressed outpatients.

Authors:  J Mendels; M M Amin; G Chouinard; A J Cooper; J E Miles; R A Remick; B Saxena; S K Secunda; A N Singh
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

5.  The effects of tricyclic antidepressants on performance under a differential-reinforcement-of-low-rates schedule in rats.

Authors:  P S McGuire; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

6.  Monoamine oxidase inhibitors. A review of antidepressant effectiveness.

Authors:  F Quitkin; A Rifkin; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1979-07

7.  Differential effects of imipramine in rats as a function of DRL schedule value.

Authors:  P S McGuire; L S Seiden
Journal:  Pharmacol Biochem Behav       Date:  1980-11       Impact factor: 3.533

8.  A new behavioral test for antidepressant drugs.

Authors:  S Nomura; J Shimizu; M Kinjo; H Kametani; T Nakazawa
Journal:  Eur J Pharmacol       Date:  1982-09-24       Impact factor: 4.432

9.  Effects of bupropion on body weight.

Authors:  N Harto-Truax; W C Stern; L L Miller; T L Sato; A E Cato
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

10.  Trazodone, a triazolopyridine derivative, in primary depressive disorder.

Authors:  J P Feighner
Journal:  J Clin Psychiatry       Date:  1980-07       Impact factor: 4.384

View more
  15 in total

1.  The effect of changes in criterion value on differential reinforcement of low rate schedule performance.

Authors:  Matthew J Pizzo; Kimberly Kirkpatrick; Pamela J Blundell
Journal:  J Exp Anal Behav       Date:  2009-09       Impact factor: 2.468

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  Effects of desipramine and fluvoxamine on timing behavior investigated with the fixed-interval peak procedure and the interval bisection task.

Authors:  M Y Ho; S S al-Zahrani; D N Velazquez Martinez; M Lopez Cabrera; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

4.  Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time greater than 72-s schedule.

Authors:  G T Pollard; J L Howard
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Effect of the experimental antidepressant AHR-9377 on performance during differential reinforcement of low response rate.

Authors:  J M O'Donnell; L S Seiden
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior.

Authors:  G J Marek; L S Seiden
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  The alpha 2-adrenoceptor antagonists idazoxan and yohimbine increase rates of DRL responding in rats.

Authors:  D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Can the DRL 72s schedule selectively reveal antidepressant drug activity?

Authors:  A Jackson; W Koek; F C Colpaert
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  DRL interresponse-time distributions: quantification by peak deviation analysis.

Authors:  J B Richards; K E Sabol; L S Seiden
Journal:  J Exp Anal Behav       Date:  1993-09       Impact factor: 2.468

10.  Flesinoxan shows antidepressant activity in a DRL 72-s screen.

Authors:  A van Hest; M van Drimmelen; B Olivier
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.